London-based AI medtech startup BioBeats has closed a $3 million funding round. The round was led by Oxford Sciences Innovation (OSI), White Cloud, and IQ Capital.
BioBeats features a wellbeing course and app that helps one to understand where their stress one comes from, and how to cope with and reduce it. By harnessing user data, artificial intelligence, and human insight, BioBeats provides an ever-improving cycle of evidence-based interventions, finding patterns that link stress to health risks and physical outcomes.
“For BioBeats, our vision is to disrupt the way stress is viewed and treated on a global scale," said Dr. David Plans, Founder and CSO of BioBeats. "Our approach focuses on challenging the conventional approach to addressing the pandemic of stress and its relation to mental health, cardiovascular disease, and other poor health outcomes; we are truly at a turning point in the digital health revolution, and this latest round of funding will help us achieve remarkable advances for our platform.”
Since 2013, BioBeats has conducted a number of successful clinical trials with BUPA, AXA, and the Center for Digital Economy at the University of Surrey, focused on gathering proof of the efficacy of BioBeats workforce wellbeing management platform.